Avigen Logo
About Avigen Research & Development Pipeline Clinical Trials Investors Contact Us
 

AV 411

  • ++ Neurology Reviews, March 2009 (Vol. 17, No. 3), "Glial Cells – A New Target for Chronic Pain Treatment”
  • ++ Rolan, P., J. Gibbons, et al. (2008). "Ibudilast in healthy volunteers: Safety, tolerability and pharmacokinetics with single and multiple doses." Br J Clin Pharmacol.  2008 Dec; 66(6); 792-801.
  • ++ Hutchinson, M. R., S. S. Lewis, et al. (2008). "Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)." Brain Behav Immun. 2009 Feb; 23(2): 240-50.
  • ++ A.L. Ellis, et al., "Characterization of exaggerated pain behavior and glial activation in a novel rat model of spinal cord injury," poster from 38th Annual Meeting of the Society for Neuroscience, Nov. 2008
  • M.R. Hutchinson, et al, abstract, “Improving the safety and efficacy of opioids by attenuating glial activation: clinical implications & the search for the novel glial activation site,” 37th Annual Meeting of the Society for Neuroscience, Nov. 2007
  • ++ Hutchinson, et al.  Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence and reward.  NIDA-requested review in The Scientific World Journal 2007; 7(S2), 98-111
  • Ledeboer, A., et al, Johnson, K.W., et al., and Watkins, L.R.  Intrathecal Interleukin-10 Gene Therapy Attenuates Paclitaxel-Induced Mechanical Allodynia and Proinflammatory Cytokine Expression in Dorsal Root Ganglia in Rats.  Brain, Behavior, Immunity (Glia/Pain special issue), Brain Behav Immun. 2007; 21:686-698
  • ++ Ledeboer, A. et al, and Johnson, K.W.  The Glial Modulatory Drug AV411 Attenuates Mechanical Allodynia in Rat Models of Neuropathic Pain.  Neuron Glia Biology (Pain special issue) 2007; 2:279-291
  • Ledeboer, A., Hutchinson, M., Watkins, L., and Johnson, K.  Ibudilast (AV411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.  Expert Opinion on Investigational Drugs, 2007; 16:935-950
  • Linda R. Watkins et al, “Glia as the ‘bad guys’: Implications for improving clinical pain control and the clinical utility of opioids,” Norman Cousins Lecture, Brain, Behavior, and Immunity, 2007; 21:131-146
  • Claypool et al, AV411 poster, “Phosphodiesterase inhibition by AV411 (ibudilast) may contribute to its efficacy in rat models of acute nociception and paclitaxel-induced neuropathic pain.”  Soc. for Neuroscience, Nov. 2007
  • Gross et al, AV1013 poster, “AV1013, A Novel orally active glial inhibitor, attenuates mechanical allodynia in rat pain models.”  Mechanisms and Treatment of Neuropathic Pain, Nov. 2007
  • Ledeboer et al, abstract, “Novel approaches to control paclitaxel-induced neuropathic pain: Efficacy of interleukin-10 gene therapy and the blood-brain barrier permeable glial modulator, AV411,” Brain, Behavior, and Immunity, May 2006; v. 20, issue 3, Supplement 1: p. 43
  • Ledeboer et al, abstract, “AV411, a blood-brain barrier permeable glial inhibitor, attenuates chronic constriction injury (CCI)- and paclitaxel-induced neuropathic pain,” The Journal of Pain, April 2006; v. 7, issue 4, Supplement S: p. 7
  • Ledeboer, E.M. Sloane, E.D. Milligan, S.J. Langer, S.F. Maier, K.W. Johnson, L.A. Leinwand, R.A. Chavez, L.R. Watkins, “Paclitaxel-induced mechanical allodynia in rats is inhibited by spinal delivery of plasmid DNA encoding interleukin-10.” In: H. Flor, E. Kalso, J.O. Dostrovsky (Eds): Proceedings of the 11th World Congress on Pain, International Association for the Study of Pain, 2006, pp.187-194
  • Lewis et al, AV411 poster, “AV411, a blood brain barrier permeable glial activation inhibitor, reduces morphine withdrawal behaviors in rats,” Soc. for Neuroscience, Oct. 2006
  • Liu et al, AV411 poster, “AV411, A Novel attenuator of neuropathic pain (and morphine withdrawal),” Mechanisms and Treatment of Neuropathic Pain, Nov. 2005
  • E.D. Milligan, S.J. Langer, E.M. Sloane et al, “Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10,” Eur J. Neurosci., 2005; 21:2136-2148
  • E.D. Milligan, E.M. Sloane, S.J. Langer et al, “Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10,” Mol Pain. 2005; 1:9
  • Tetsuya Mizuno et al, “Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia,” Neuro Pharmacology, 2004; 46: 404-411
  • Linda R. Watkins and Steven F. Maier – “When good pain turns bad,” Current Directions in Psychological Science, 2003; vol. 12, no. 6:232-236
  • Vesa K. Kontinen and Theo F. Meert, “Predictive Validity of Neuropathic Pain Models in Pharmacological Studies with a Behavioral Outcome in the Rat: A Systematic Review,” Proceedings of the 10th World Congress on Pain, 2003; 24:489-498
  • K.M. Foley, “Opioids and chronic neuropathic pain,” N Engl J Med. 2003; 348:1279-1281
  • “Decade of pain control and research: Now is the time to do something about America's pain crisis” [press release]. American Pain Society; September 24, 2003
  • M. Pohl, A. Meunier, M. Hamon, J. Braz, “Gene therapy of chronic pain,” Curr Gene Ther., 2003; 3:223-238
  • W.F. Stewart, J.A. Ricci, E. Chee, D. Morganstein, R. Lipton, “Lost productive time and cost due to common pain conditions in the U.S. workforce,” JAMA. 2003; 290:2443-2454
  • T. Hampton, “Researchers probe pathways of pain: new insights emerging from molecular studies,” JAMA, 2003; 290:2391-2392
  • M.L. Meldrum, “A capsule history of pain management,” JAMA, 2003; 290:2470-2475
  • J. C. Ballantyne, J. Mao, “Opioid therapy for chronic pain,” N Engl J Med., 2003; 349:1943-1953
  • L. R. Watkins, S.F. Maier, “Glia: a novel drug discovery target for clinical pain,” Nat Rev Drug Discov. 2003; 2:973-985
  • M.B. Max, “How to move pain and symptom research from the margin to the mainstream,” J Pain. 2003; 4:355-360
  • Linda R. Watkins and Steven F. Maier, “Beyond Neurons: Evidence That Immune and Glial Cells Contribute to Pathological Pain States,” Physiological Reviews, 2002; 82:981-1011
  • Linda S. Sorkin, “Neuroinflammation, cytokines and neuropathic pain” (book chapter, Mechanisms and Mediators of Neuropathic Pain), Annika B. Malmberg and Sandra R. Chaplan, editors, 2002
  • B.A. Vogt, “Knocking out the DREAM to study pain,” N Engl J Med., 2002; 347:362-364
  • Package Insert – Ketas®, 2003
  • Package Insert – Cymbalta®, 2005
  • Package Insert - Neurontin®, 2005
  • Package Insert - Lyrica®, 2009